Compare AbbVie Inc (ABBV) vs The Coca-Cola Co K (KO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs The Coca-Cola Co K — how do they compare? AbbVie Inc trades at $249.96 (market cap $441.94B), while The Coca-Cola Co K trades at $86.88 (market cap $372.08B). The key difference: AbbVie Inc is the larger of the two by market cap, and AbbVie Inc pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| ABBV | KO | |
|---|---|---|
Market Cap | $441.94B | $372.08B |
Sector | Health | Consumer Staples |
52-Week High | $263.58 | $89.08 |
52-Week Low | $197.38 | $65.67 |
Enterprise Value | $506.19B | $399.26B |
Dividend Yield | 2.77% | 2.45% |
Volume | — | 14,630,257 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $247.91, up 0.76% today, with a bullish technical signal and strong analyst support. Recent earnings beats and a 70.73% buy consensus highlight robust fundamentals, driven by Skyrizi and Rinvoq growth offsetting Humira declines. Positive news includes Phase 2 ovarian cancer data and institutional stake increases, reinforcing momentum.
Outlook remains positive with a $278.69 price target, though risks include patent cliffs and debt levels. Revenue growth and dividend stability offer appeal, but investors should monitor competitive pressures and regulatory developments for sustained performance.
Coca-Cola (KO) trades at $86.87, down 0.21% today, with a bullish technical signal supported by moving averages and RSI near 69. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $0.97 exceeding expectations, and maintains robust profitability with a 28.56% net margin. Recent news highlights institutional buying and stable demand trends ahead of Q3 earnings.
KO offers a solid dividend history with 64 consecutive years of increases, but faces risks from regional demand divergence and high debt. Analysts are bullish with a $95.83 price target, implying 10% upside, though valuation multiples like P/E of 25.97 suggest premium pricing relative to peers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About The Coca-Cola Co K
The Coca-Cola Company manufactures, markets, and distributes soft drink concentrates and syrups. The Company also distributes and markets juice and juice-drink products. Coca-Cola distributes its products to retailers and wholesalers in the United States and internationally.
Read more on KO →
